Lilly to buy AtaiBeckley for USD 6.75 per share plus CVR up to USD 2.5

Eli Lilly and Company

LLY

0.00

Eli Lilly agreed to buy AtaiBeckley for USD 6.75 a share in cash, valuing the equity at about USD 2.8 billion.
Deal includes a contingent value right of up to USD 2.5 a share tied to development and US approval milestones for BPL-003, VLS-01.
AtaiBeckley’s lead asset BPL-003, an intranasal synthetic 5-MeO-DMT, is in Phase 3 activities for treatment-resistant depression.
Transaction is expected to close in the third quarter, pending AtaiBeckley shareholder vote and regulatory clearances.
Offer represents about a 40% premium to AtaiBeckley’s 30-day volume-weighted average price through July 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160645PR_NEWS_USPR_____DE06036) on July 16, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.